Health Care
In spite of positive regulatory and business news, health stocks held to the rest of the markets on Thursday leaving biotech indices a bit in the red.
Noven Pharmaceuticals(NOVN) said Wednesday after the close that the U.S. Food and Drug Administration sent a tentative approval letter for the company's Stavzor. The drug is for manic episodes related to bipolar disorder and used as a therapy for multiple types of seizures, as well as a preventative for migraine headaches. Tentative approval generally indicates the agency has concluded that a drug has met the required quality, safety and efficacy standards, but it cannot be marketed in the U.S. yet due to existing patents and/or exclusivity rights, according to the company. Noven expects the FDA's final approval by the end of July 2008. Shares rose a bit and then fell back 25 cents, or 1.72%, to $14.80 on Thursday. On the business side, Cell Therapeutics Inc.(CTIC) said Thursday that it completed the buyout of Biogen Idec's(BIIB) Zevalin for non-Hodgkin's Lymphoma (NHL). The drug is approved for NHL patients who've tried another therapy unsuccessfully. Per the deal announced in August, CTI made an upfront payment of $10 million in exchange for control of U.S. marketing, sales and development of Zevalin, and will pay an additional $20 million in milestone payments if Zevalin is approved as a first line, or initial, treatment for NHL. CTI will also pay sales royalties for Zevalin until at least December 2015, according to the companies.TheStreet Premium Services
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn MoreOptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn MoreReal Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn MoreStocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,393.45 | 1,310.33 | 2,827.34 | 15.81 |
Oil *
101.78
|
|
DOWN
26.41 |
DOWN
2.99 |
DOWN
10.02 |
DOWN
0.44 |
10 Yr
1.58%
SPDR Gold
151.62
|
|
-0.21%
|
-0.23%
|
-0.35%
|
-2.71%
|
Data delayed 20 minutes |


Connect with TheStreet